Table 2: Clinical information at hospitalization.
|
n (%) or median [IQR] |
n (%) or median [IQR] |
|
Onset of symptoms and hospital admission (days) |
7.0 [4.0-9.5] |
Pharmacological treatments |
|
Oxygen supplementation |
|
Antibiotic (except azithromycin) |
359 (79.7) |
Nasal catheter (NC) |
247 (55.5) |
Azithromycin |
340 (75.0) |
Hudson mask |
86 (19.3) |
Corticosteroid |
283 (61.9) |
Noninvasive ventilation (NIV) |
76 (17.0) |
Anticoagulant* |
138 (31.8) |
High flow nasal cannula (HFNC) |
62 (13.9) |
Antiviral (oseltamivir) |
130 (29.6) |
Mechanical ventilation (MV) |
97 (21.1) |
Hydroxychloroquine |
115 (25.1) |
Oxygen therapy combination |
|
Convalescent plasma |
76 (16.5) |
NC → Hudson mask |
79 (17.7) |
Vasopressor |
69 (15.7) |
NC → Hudsonmask → NIV |
48 (10.8) |
Anti-IL6 drugs (tocilizumab) |
12 (2.6) |
NC → Hudsonmask → NIV → HFNC |
26 (5.8) |
Azithromycin + Corticosteroid |
116 (25.6) |
NC → Hudsonmask → NIV → HFNC → MV |
23 (5.1) |
Azithromycin + Corticosteroid + Anticoagulant |
78 (17.2) |
Intensive care unit (ICU) |
136 (29.6) |
Outcomes |
|
ICU length of stay (days) |
15.1 [7.1-29.5] |
Hospital discharge |
398 (86.7) |
With MV |
25.2 [11.1-37.0] |
Death |
40 (8.7) |
Without MV |
7.2 [5.3-10.5] |
Censored** |
21 (4.5) |
ICU: Intensive care unit; MV: Mechanical ventilation; *Anticoagulation used with treatment intention; **Censored means patients without outcome results